English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/184614
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease

AuthorsSanchis, Ana ; García-Gimeno, María Adelaida ; Cañada-Martínez, Antonio José; Sequedo, María Dolores; Millán, José María; Sanz, Pascual ; Vázquez-Manrique, Rafael P.
Issue Date5-Jun-2019
PublisherSpringer Nature
CitationExperimental and Molecular Medicine 51(6):65 (2019)
AbstractHuntington disease is a neurodegenerative condition for which there is no cure to date. Activation of AMP-activated protein kinase has previously been shown to be beneficial in in vitro and in vivo models of Huntington's disease. Moreover, a recent cross-sectional study demonstrated that treatment with metformin, a well-known activator of this enzyme, is associated with better cognitive scores in patients with this disease. We performed a preclinical study using metformin to treat phenotypes of the zQ175 mouse model of Huntington disease. We evaluated behavior (motor and neuropsychiatric function) and molecular phenotypes (aggregation of mutant huntingtin, levels of brain-derived neurotrophic factor, neuronal inflammation, etc.). We also used two models of polyglutamine toxicity in Caenorhabditis elegans to further explore potential mechanisms of metformin action. Our results provide strong evidence that metformin alleviates motor and neuropsychiatric phenotypes in zQ175 mice. Moreover, metformin intake reduces the number of nuclear aggregates of mutant huntingtin in the striatum. The expression of brain-derived neurotrophic factor, which is reduced in mutant animals, is partially restored in metformin-treated mice, and glial activation in mutant mice is reduced in metformin-treated animals. In addition, using worm models of polyglutamine toxicity, we demonstrate that metformin reduces polyglutamine aggregates and restores neuronal function through mechanisms involving AMP-activated protein kinase and lysosomal function. Our data indicate that metformin alleviates the progression of the disease and further supports AMP-activated protein kinase as a druggable target against Huntington's disease.
Description16 páginas, 8 figuras, 1 tabla
Publisher version (URL)http://dx.doi.org/10.1038/s12276-019-0264-9
URIhttp://hdl.handle.net/10261/184614
DOI10.1038/s12276-019-0264-9
ISSN1226-3613
E-ISSN2092-6413
Appears in Collections:(IBV) Artículos
Files in This Item:
File Description SizeFormat 
2019 Exp Mol Med 51-65.pdf7,32 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.